Meeting
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
Authors
Yan Zhang
Department of Thoracic Oncology, Cancer Centre, Sichuan University West China Hospital, Chengdu, China
Yan Zhang , Lin Zhou , Youling Gong , Meijuan Huang , Min Tang , Yongmei Liu , Min Yu , Weigang Xiu , Xinjun Liang , Xinyu Liu , Xin-Yuan Fu , You Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
CTR20212486
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9112)
DOI
10.1200/JCO.2023.41.16_suppl.9112
Abstract #
9112
Poster Bd #
100
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1 dose-finding and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of a highly selective WEE1 inhibitor (Debio 0123) in adult patients with advanced solid tumors.
First Author: Kyriakos P. Papadopoulos
Poster
2022 ASCO Annual Meeting
An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
First Author: Kaiwen Li
Poster
2022 ASCO Annual Meeting
A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale.
First Author: Omar Saavedra Santa Gadea
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.
First Author: Ramaswamy Govindan